SCHEMBL1542696

SCHEMBL1542696

Cc1nc(-c2ccccc2)ccc1C(=O)Nc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.67
CYP3A4 P08684 2/20 0.56
CHRNB2 P17787 1/20 0.55
CHRNB4 P30926 1/20 0.55
CHRNA3 P32297 1/20 0.55
CHRNA4 P43681 1/20 0.55
POLB P06746 1/20 0.54
MAPK1 P28482 1/20 0.54
SMO Q99835 1/20 0.53
HPGD P15428 2/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
TACR3 P29371 1/20 0.52
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
MAPT P10636 2/20 0.51
TRPV1 Q8NER1 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
RXFP1 Q9HBX9 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31610122 0.84 ATR (0.52) ALDH1A1CYP3A4HPGDSMN1; SMN2NPC1
SCHEMBL1542967 0.83 CYP3A4 (0.57) ALDH1A1CYP3A4CHRNB2CHRNB4CHRNA3
SCHEMBL10903716 0.83 L3MBTL1 (0.57) ALDH1A1POLBMAPK1HPGDNPC1
SCHEMBL31171326 0.83 L3MBTL1 (0.57) ALDH1A1POLBMAPK1HPGDNPC1
SCHEMBL4422133 0.80 TRPV1 (0.66) ALDH1A1CYP3A4POLBNPC1RAB9A
SCHEMBL4429929 0.80 ALDH1A1 (1.00) ALDH1A1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL10991381 0.79 HPGD (0.61) ALDH1A1POLBMAPK1HPGDSMN1; SMN2
SCHEMBL1543123 0.79 RAB9A (0.59) ALDH1A1POLBHPGDSMN1; SMN2NPC1
SCHEMBL1542654 0.79 ALDH1A1 (0.58) ALDH1A1MAPK1HPGDSMN1; SMN2NPC1
SCHEMBL1543011 0.79 ALDH1A1 (0.58) ALDH1A1POLBMAPK1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306597-A1 Nicotinamide Derivatives CRAWFORTH JAMES MICHAEL (GB) 2011-12-15 US claimed
JP-2011524894-A 2011-09-08 JP claimed
EP-2307378-A1 NICOTINAMIDE DERIVATIVES Pfizer Limited (GB) 2011-04-13 EP claimed
WO-2009153721-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO claimed
US-20110306597-A1 Nicotinamide Derivatives CRAWFORTH JAMES MICHAEL (GB) 2011-12-15 US disclosed
EP-2307378-A1 NICOTINAMIDE DERIVATIVES Pfizer Limited (GB) 2011-04-13 EP disclosed
WO-2009153721-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306597-A1 Nicotinamide Derivatives NNT, NAMPT, NQO1 ALDH1A1 172/4885CYP3A4 226/4885CHRNB2 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.